Opendata, web and dolomites

EpiTune SIGNED

Epigenetic fine-tuning of T cells for improved adoptive cell therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EpiTune project word cloud

Explore the words cloud of the EpiTune project. It provides you a very rough idea of what is the project "EpiTune" about.

molecular    equip    mechanisms    transplantation    differentiation    fine    epigenetic    immunosuppressive    cells    environment    methylation    survival    epi    chronic    basic    strategies    stable    dna    immunity    efficiency    reveal    structure    functional    harbor    senescence    acquisition    crispr    epigenome    cellular    settings    effect    patient    angle    hampered    editing    organ    successful    auto    vitro    safety    essentially    infusion    utilizing    developmental    plasticity    therapeutic    imprint    limits    opposite    clinical    manipulation    encounter    inflammatory    epigenetically    mechanism    genomic    expansion    innovative    stability    combating    cas9    mediated    directed    desired    undesired    reactivity    fitness    tuning    switch    lymphocytes    transfusion    therapy    cell    fighting    pro    manipulations    modifications    players    cancer    obstacles    reconstitution    tackle    prospect    imprinting    sensitive    immune    safe    profound    goals    shot    adoptive    infections   

Project "EpiTune" data sheet

The following table provides information about the project.

Coordinator
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

Organization address
address: Chariteplatz 1
city: BERLIN
postcode: 10117
website: www.charite.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙489˙725 €
 EC max contribution 1˙489˙725 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) coordinator 1˙489˙725.00

Map

 Project objective

'Adoptive T cell therapy is a promising approach in various clinical settings, from target-specific immune reconstitution fighting cancer and chronic infections to combating undesired immune reactivity during auto-immunity and after organ transplantation. However, its clinical application is currently hampered by: 1) the acquisition of senescence during the required in vitro expansion phase of T cells which limits their survival and fitness after infusion into the patient, and 2) the functional plasticity of T cells, which is sensitive to the inflammatory environment they encounter after transfusion and which might result in a functional switch from the desired effect (e.g. immunosuppressive) to the opposite one (pro-inflammatory). I want to tackle these obstacles from a new molecular angle, utilizing the profound impact of epigenetic mechanisms on the senescence process as well as on the functional imprinting of T lymphocytes. Epigenetic players such as DNA methylation essentially contribute to T cell differentiation and harbor the unique prospect to imprint a stable developmental and functional state in the genomic structure of a cell, as we could recently show in our basic immune-epigenetic studies. Therefore, I here propose to equip T lymphocytes with the required properties for their successful and safe therapeutic application, including their functional fine-tuning according to the clinical need by directed modifications of the epigenome ('Epi-tuning'). To reach these goals I want: 1) to reveal strategies for the directed manipulation of the epigenetically-driven mechanism of cellular senescence and 2) to apply state-of-the-art CRISPR/Cas9-mediated epigenetic editing approaches for the imprinting of a desired functional state of therapeutic T cell products. These innovative epigenetic 'one-shot' manipulations during the in vitro expansion phase should advance T cell therapy towards improved efficiency, stability as well as safety.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPITUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPITUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

NEUTRAMENTH (2018)

A redox-neutral process for the cost-efficient and environmentally friendly production of Menthol

Read More  

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More